| Cidara Therapeutics to Host Virtual R&D Day to Discuss CD388 as a Potential Universal, Once-Per-Flu Season Preventative of Seasonal and Pandemic Influenza on May 22, 2025 |
SAN DIEGO, May 15, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced that it will host a virtual research and development (R&D) day on Thursday, May 22, 2025, from 10:00 to 11:30 AM ET. To register, click here. |
globenewswire.com |
2025-05-15 12:00:00 |
Czytaj oryginał (ang.) |
| Cidara Therapeutics to Participate in Two Upcoming Investor Conferences |
SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced that company management will participate in the below investor conferences. Event: RBC Global Healthcare Conference Date: Wednesday, May 21, 2025 Time: 10:00 AM ET Event: Jefferies Global Healthcare Conference Date: Wednesday, June 4, 2025 Time: 11:40 AM ET The live webcast for the presentations can be accessed in the Investors section on the Company's website at https://www.cidara.com/investors/events/. |
globenewswire.com |
2025-05-13 12:00:00 |
Czytaj oryginał (ang.) |
| Cidara Therapeutics, Inc. (CDTX) Q1 2025 Earnings Call Transcript |
Cidara Therapeutics, Inc. (NASDAQ:CDTX ) Q1 2025 Earnings Conference Call May 8, 2025 5:00 PM ET Company Participants Brian Ritchie - LifeSci Advisors Jeffrey Stein - President and Chief Executive Officer Frank Karbe - Chief Financial Officer Nicole Davarpanah - Chief Medical Officer Les Tari - Chief Scientific Officer Jim Beitel - Chief Business Officer Conference Call Participants Eric Schmidt - Cantor Fitzgerald Seamus Fernandez - Guggenheim Gregory Renza - RBC Capital Markets Joseph Stringer - Needham & Company Roy Buchanan - Citizens Bank Operator Greetings. Welcome to Cidara's Q1 2025 Earnings Call. |
seekingalpha.com |
2025-05-11 01:29:23 |
Czytaj oryginał (ang.) |
| Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results |
SAN DIEGO, May 08, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today reported financial results for the first quarter ended March 31, 2025, and provided recent business updates. |
globenewswire.com |
2025-05-08 20:15:00 |
Czytaj oryginał (ang.) |
| Cidara Therapeutics: Strong Buy On Imminent Data Readout For Lead Flu Candidate |
We initiate coverage on Cidara Therapeutics with a Strong Buy rating due to its strategic pivot to antiviral CD388 and promising Phase 2b trial data. Rezafungin's successful approval and divestiture to Mundipharma validate Cidara's development capabilities and free resources for advancing CD388. CD388 shows potential for season-long influenza protection, with promising Phase 2a data and a well-funded Phase 2b trial targeting high-risk patients. |
seekingalpha.com |
2025-05-05 09:00:07 |
Czytaj oryginał (ang.) |
| Cidara Therapeutics Announces Promotion of Nicole Davarpanah to Chief Medical Officer and Corrina Pavetto to SVP, Clinical Development |
SAN DIEGO, May 01, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced that Nicole Davarpanah, M.D., J.D. has been promoted to chief medical officer (CMO), and Corrina Pavetto has been promoted to senior vice president, clinical development, effective May 1, 2025. |
globenewswire.com |
2025-05-01 12:00:00 |
Czytaj oryginał (ang.) |
| Are You Looking for a Top Momentum Pick? Why Cidara Therapeutics (CDTX) is a Great Choice |
Does Cidara Therapeutics (CDTX) have what it takes to be a top stock pick for momentum investors? Let's find out. |
zacks.com |
2025-04-30 17:00:59 |
Czytaj oryginał (ang.) |
| Cidara Therapeutics to Participate in The Citizens Life Sciences Conference |
SAN DIEGO, April 30, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced that company management will participate in The Citizens Life Sciences Conference. Details are as follows: Event: The Citizens Life Sciences Conference Date: Wednesday, May 7, 2025 Time: 11:00 AM ET Format: Presentation Webcast: https://wsw.com/webcast/jmp65/cdtx/1686102 A replay of the presentation will be available in the Investors section on the Company's website at www.cidara.com. |
globenewswire.com |
2025-04-30 12:00:00 |
Czytaj oryginał (ang.) |
| Phathom Pharmaceuticals Appoints Ted Schroeder to its Board of Directors |
FLORHAM PARK, N.J., April 16, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced the appointment of Ted Schroeder to its Board of Directors. |
globenewswire.com |
2025-04-16 12:00:00 |
Czytaj oryginał (ang.) |
| Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) |
SAN DIEGO, April 01, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies, today announced that the Compensation and Human Capital Committee of its Board of Directors (Compensation Committee) granted Timothy Alefantis, a new employee, a non-qualified stock option award and restricted stock units (RSUs) for an aggregate of 27,000 shares of its common stock, pursuant to the Cidara Therapeutics, Inc. 2020 Inducement Incentive Plan, as amended (the Inducement Plan), with a grant date of March 31, 2025. The stock option has an exercise price of $21.54 per share, which is equal to the closing price of Cidara's common stock on the grant date. The shares subject to the option will vest over four years, with 25% of the shares vesting on the one-year anniversary of the vesting commencement date and the balance of the shares vesting in a series of 36 successive equal monthly installments thereafter. All RSUs vest in four equal annual installments, with 1/4 vesting on each of the first, second, third and fourth anniversaries of the Quarterly Vesting Date (as defined below) that occurs during the calendar quarter that includes the date of grant. “Quarterly Vesting Date” means March 10, June 10, September 10 or December 10. The awards are subject to the award holder's continuous service through each vesting date and to the terms and conditions of the Inducement Plan and the standard forms of grant agreements thereunder. |
globenewswire.com |
2025-04-01 20:56:00 |
Czytaj oryginał (ang.) |
| Cidara Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference |
SAN DIEGO, April 01, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies, today announced that company management will participate in the 24th Annual Needham Virtual Healthcare Conference. Details are as follows: Event: 24th Annual Needham Virtual Healthcare Conference Date: Wednesday, April 9, 2025 Time: 11:00 AM ET Format: Presentation Webcast: https://wsw.com/webcast/needham146/cdtx/2261559 A replay of the presentation will be available in the Investors section on the Company's website at www.cidara.com. |
globenewswire.com |
2025-04-01 20:05:00 |
Czytaj oryginał (ang.) |
| Wall Street Analysts Predict a 64.5% Upside in Cidara Therapeutics (CDTX): Here's What You Should Know |
The consensus price target hints at a 64.5% upside potential for Cidara Therapeutics (CDTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. |
zacks.com |
2025-03-21 12:55:28 |
Czytaj oryginał (ang.) |
| Cidara Therapeutics to Participate in World Health Organization Meeting on H5N1 Influenza Preparedness and Response |
SAN DIEGO, March 19, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies, today announced participation in the “Other pharmaceuticals as preventive tools” panel at a World Health Organization (WHO) global meeting on H5N1 influenza preparedness and response. The meeting, titled “What research is important to prepare and respond to H5N1 influenza outbreaks,” will be held virtually on March 19, 2025, from 1:00-7:15pm Central European Time (CET)/5:00-11:15am Pacific Time (PT), and the panel discussion will take place from 6:30-7:00 pm CET/10:30-11:00am PT. |
globenewswire.com |
2025-03-19 10:00:00 |
Czytaj oryginał (ang.) |
| Cidara Therapeutics Announces Two Presentations on CD388 in Influenza at International Conference on Antiviral Research (ICAR) 2025 |
SAN DIEGO, March 18, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies, today announced two upcoming presentations at the 38th International Conference on Antiviral Research (ICAR). The conference takes place from March 17-21, 2025 in Las Vegas, Nevada. |
globenewswire.com |
2025-03-18 10:00:00 |
Czytaj oryginał (ang.) |
| Cidara Therapeutics Announces Publication of CD388 Preclinical Data in Nature Microbiology |
Data highlights potential of CD388 as a potent, universal antiviral for influenza prevention regardless of immune status |
globenewswire.com |
2025-03-17 08:00:00 |
Czytaj oryginał (ang.) |
| Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results |
SAN DIEGO, March 06, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies, today reported financial results for the fourth quarter and full year ended December 31, 2024 and provided recent business updates. |
globenewswire.com |
2025-03-06 18:35:00 |
Czytaj oryginał (ang.) |
| Cidara Therapeutics Announces Appointment of Frank Karbe as Chief Financial Officer |
Industry veteran CFO Frank Karbe brings more than 25 years of leadership experience in the biopharma industry transitioning companies from R&D to commercialization Industry veteran CFO Frank Karbe brings more than 25 years of leadership experience in the biopharma industry transitioning companies from R&D to commercialization |
globenewswire.com |
2025-02-18 18:15:00 |
Czytaj oryginał (ang.) |
| Bullish On Cidara Therapeutics As It Doubles Down On CD388 For Universal Flu Prevention |
Cidara Therapeutics is leveraging its Cloudbreak platform to develop CD388 for universal influenza prophylaxis. Fortunately, they recently enrolled 5,000 subjects in its Phase 2b trial to assess CD388's safety and efficacy. CD388 inhibits viral replication and activates the immune response, and its mechanism of action actually received the FDA's Fast Track designation. |
seekingalpha.com |
2025-02-11 10:22:36 |
Czytaj oryginał (ang.) |
| Cidara Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference |
SAN DIEGO, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, will participate in the Guggenheim Securities SMID Cap Biotech Conference. |
globenewswire.com |
2025-01-30 18:05:00 |
Czytaj oryginał (ang.) |
| Cidara Therapeutics (CDTX) Just Flashed Golden Cross Signal: Do You Buy? |
Cidara Therapeutics, Inc. (CDTX) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, CDTX's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross. |
zacks.com |
2024-12-03 12:55:43 |
Czytaj oryginał (ang.) |
| Cidara: Potential To Change Flu Prophylaxis Landscape With CD388 |
Results from phase 2b NAVIGATE study, using CD388 as a prophylaxis for Flu, expected to be released Q3 of 2025. CD388 offers broad influenza A and B coverage regardless of strain type and even effective in immunocompromised patients, and could revolutionize flu treatment. The global influenza vaccine market is projected to grow to $17.77 billion by 2032. |
seekingalpha.com |
2024-11-21 17:12:05 |
Czytaj oryginał (ang.) |
| Cidara Therapeutics Announces $105 Million Private Placement |
Financing led by new investor, Venrock Healthcare Capital Partners, with significant participation by new and existing life sciences-focused investors Financing led by new investor, Venrock Healthcare Capital Partners, with significant participation by new and existing life sciences-focused investors |
globenewswire.com |
2024-11-21 10:30:00 |
Czytaj oryginał (ang.) |
| Cidara Therapeutics to Participate in Evercore 7th Annual HealthCONx Conference |
SAN DIEGO, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, will participate in the Evercore 7th Annual HealthCONx Conference. |
globenewswire.com |
2024-11-19 10:00:00 |
Czytaj oryginał (ang.) |
| Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results |
SAN DIEGO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today reported financial results for the third quarter ended September 30, 2024, and provided an update on its corporate activities and product pipeline. |
globenewswire.com |
2024-11-07 18:15:00 |
Czytaj oryginał (ang.) |
| Cidara Therapeutics to Participate in Two Upcoming November Investor Conferences |
SAN DIEGO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, will participate in the following November investor conferences. |
globenewswire.com |
2024-10-31 10:00:00 |
Czytaj oryginał (ang.) |
| Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) |
SAN DIEGO, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced that the Compensation Committee of its Board of Directors (Compensation Committee) granted Dipesh Bhatt, a new employee, a non-qualified stock option award and restricted stock units (RSUs) for an aggregate of 1,110 shares of its common stock, pursuant to the Cidara Therapeutics, Inc. 2020 Inducement Incentive Plan, as amended (the Inducement Plan), with a grant date of September 30, 2024. The stock option has an exercise price of $10.75 per share, which is equal to the closing price of Cidara's common stock on the grant date. The shares subject to the option will vest over four years, with 25% of the shares vesting on the one-year anniversary of the vesting commencement date and the balance of the shares vesting in a series of 36 successive equal monthly installments thereafter. All RSUs vest in four equal annual installments, with 1/4 vesting on each of the first, second, third and fourth anniversaries of the Quarterly Vesting Date (as defined below) that occurs during the calendar quarter that includes the date of grant. “Quarterly Vesting Date” means March 10, June 10, September 10 or December 10. The awards are subject to the award holder's continuous service through each vesting date and to the terms and conditions of the Inducement Plan and the standard forms of grant agreements thereunder. |
globenewswire.com |
2024-10-04 20:30:00 |
Czytaj oryginał (ang.) |
| Cidara Therapeutics Announces Two Presentations on Innovative Drug-Fc Conjugate, CD388, at the 2024 OPTIONS XII for the Control of Influenza Conference |
SAN DIEGO, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced two presentations at OPTIONS XII for the Control of Influenza conference, to be held September 29 through October 2, 2024 in Brisbane, Australia. The presentations, one oral and one poster, will highlight safety and pharmacokinetic (PK) data from clinical studies of CD388, Cidara's influenza drug-Fc conjugate (DFC) candidate. |
globenewswire.com |
2024-09-25 12:00:00 |
Czytaj oryginał (ang.) |
| Cidara Therapeutics Announces First Subjects Dosed in Phase 2b NAVIGATE Trial Evaluating CD388 for the Prevention of Seasonal Influenza |
The Phase 2b trial will enroll 5,000 subjects across clinical sites in the US and UK The Phase 2b trial will enroll 5,000 subjects across clinical sites in the US and UK |
globenewswire.com |
2024-09-23 12:00:00 |
Czytaj oryginał (ang.) |
| Cidara Therapeutics Strengthens its Scientific Advisory Board with Infectious Disease Experts |
SAN DIEGO, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced the appointment of Rick Bright, Ph.D., Philip Krause, M.D., Mario Barro, Ph.D., and Frederick G. Hayden, M.D., FACP to its Scientific Advisory Board (SAB). |
globenewswire.com |
2024-09-19 12:00:00 |
Czytaj oryginał (ang.) |
| Cidara Therapeutics Restructures Workforce to Focus on Planned Clinical Development of CD388 |
SAN DIEGO, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced a reduction in its workforce to focus on the clinical development of CD388, the Company's novel DFC candidate for influenza A and B. The planned reduction impacts approximately 30% of the Cidara workforce. |
globenewswire.com |
2024-09-12 20:05:00 |
Czytaj oryginał (ang.) |
| Cidara to Present at the H.C. Wainwright 26th Annual Global Investment Conference |
SAN DIEGO, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, will present at the H.C. Wainwright 26th Annual Global Investment Conference. |
globenewswire.com |
2024-09-05 12:00:00 |
Czytaj oryginał (ang.) |
| Cidara Therapeutics Announces Appointment of Jim Beitel as Chief Business Officer |
Appointment adds biotech veteran with over two decades of business development, strategy, and operational experience to Cidara's management team Appointment adds biotech veteran with over two decades of business development, strategy, and operational experience to Cidara's management team |
globenewswire.com |
2024-08-19 21:12:00 |
Czytaj oryginał (ang.) |
| Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results |
SAN DIEGO, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today reported financial results for the second quarter ended June 30, 2024, and provided an update on its corporate activities and product pipeline. |
globenewswire.com |
2024-08-13 20:29:00 |
Czytaj oryginał (ang.) |
| Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) |
SAN DIEGO, July 03, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced that the Compensation Committee of its Board of Directors granted Corrina Pavetto, a new employee, a non-qualified stock option award and restricted stock units (RSUs) for an aggregate of 10,275 shares of its common stock, pursuant to the Cidara Therapeutics, Inc. 2020 Inducement Incentive Plan, with a grant date of June 28, 2024. The stock option has an exercise price of $11.94 per share, which is equal to the closing price of Cidara's common stock on the grant date. The shares subject to the option will vest over four years, with 25% of the shares vesting on the one-year anniversary of the vesting commencement date and the balance of the shares vesting in a series of 36 successive equal monthly installments thereafter. All RSUs vest in four equal annual installments, with 1/4 vesting on each of the first, second, third and fourth anniversaries of the Quarterly Vesting Date that occurs during the calendar quarter that includes the Date of Grant. Quarterly Vesting Date means March 10, June 10, September 10 or December 10. The awards are subject to the award holder's continuous service through each vesting date and to the terms and conditions of Cidara's 2020 Inducement Incentive Plan and its standard forms of grant agreements thereunder. |
globenewswire.com |
2024-07-03 17:05:00 |
Czytaj oryginał (ang.) |
| Cidara Therapeutics to Present Preclinical Data on CD388 at ASM Microbe 2024 Conference |
SAN DIEGO, May 30, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced the company will be presenting a poster at the American Society for Microbiology (ASM) Microbe 2024 conference to be held June 13-17, 2024 at the Georgia World Congress Center in Atlanta, Georgia. |
globenewswire.com |
2024-05-30 12:00:00 |
Czytaj oryginał (ang.) |
| Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results |
SAN DIEGO, May 15, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today reported financial results for the first quarter ended March 31, 2024, and provided an update on its corporate activities and product pipeline. |
globenewswire.com |
2024-05-15 20:20:00 |
Czytaj oryginał (ang.) |
| Cidara Therapeutics Regains Compliance with Nasdaq Continued Listing Rules |
SAN DIEGO, May 15, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced that on May 14, 2024 it received a letter from the Listing Qualifications Department staff (the Staff) of the Nasdaq Stock Market LLC (Nasdaq) notifying the Company that it has regained compliance with Nasdaq's requirements for continued listing. In addition, the Nasdaq Hearing Panel (the Panel) imposed a discretionary Panel monitor until May 14, 2025, such that if the Company fails to maintain compliance with any continued listing requirement during such period, the Staff will issue a delist determination letter and the Company will promptly schedule a new hearing before the Panel to address such noncompliance. |
globenewswire.com |
2024-05-15 20:01:00 |
Czytaj oryginał (ang.) |
| CDTX INVESTOR NOTICE: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Cidara Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - CDTX |
NEW YORK, May 10, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Cidara Therapeutics, Inc. (NASDAQ: CDTX) resulting from allegations that Cidara Therapeutics may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Cidara Therapeutics securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. |
prnewswire.com |
2024-05-11 01:48:00 |
Czytaj oryginał (ang.) |
| Cidara Therapeutics: Now Well-Funded To Advance Its Cloudbreak Platform |
Cidara Therapeutics, Inc. passed rezafungin rights to Mundipharma allowing reallocation of resources to the oncology Cloudbreak platform. Following a considerable private placement and re-acquisition of CD388 from Janssen, CDTX is well funded to start and complete a ph2b trial. Cidara Therapeutics no longer expects any milestone/royalty revenue but will be able to raise funds from a much stronger position following a positive ph2b trial for CD388. |
seekingalpha.com |
2024-04-26 22:01:25 |
Czytaj oryginał (ang.) |